Key facts
- Portal Biotechnologies’s last known valuation is $34.8M (Dec 2024).
- It has raised $12.0M across 2 recorded rounds; the latest was Early Stage VC ($9.0M) in May 2026.
- Notable investors include Pear (California), Page One Ventures, Scale Good Fund, IA Ventures, 10X Capital — 8 tracked in total.
- Portal Biotechnologies has filed 3 Form Ds with the SEC since 2024, most recently May 2026 ($11.7M sold to 43 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Portal Biotechnologies
Funding rounds
2 roundsAbout Portal Biotechnologies
Developer of a cell engineering platform designed to enable novel cell analytics and next-generation cell therapies. The company is implementing a simplified approach to intracellular delivery, focused on accelerating advances stimulated by the new generation of RNA, gene editing, and molecular design technologies, enabling the healthcare sector with research and clinical-scale technologies.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2023
- Employees
- 15
- Website
- portal.bio/
- Ownership
- Privately Held (backing)
Portal Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Portal Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Portal Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.